Major trials of weight-loss medications rarely register measures of reproductive function, according to a review of ClinicalTrials.gov records. Researchers examined 230 randomized trials involving adults and found that only two registered any reproductive outcome. Both involved women with polycystic ovary syndrome. None of the 228 trials enrolling men registered a named male reproductive hormone or semen measure. In contrast, 33 trials registered body-composition outcomes. The findings highlight a gap in publicly discoverable evidence, not proof that the medications harm fertility or that researchers never collected reproductive data. For patients and clinicians, the takeaway is to acknowledge uncertainty when discussing reproductive goals alongside weight management. Trial sponsors could make existing assessments easier to find by registering them. This summary is based on the abstract only.
